News

Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome

October 02, 2019

REDWOOD CITY, Calif. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical ...

Read More

Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome

September 24, 2019

Data Published for First Time in Peer-Reviewed Journal   REDWOOD CITY, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- ...

Read More

Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies

September 19, 2019

REDWOOD CITY, Calif. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More
Soleno – Home